Newsroom

latest news from ose
and across our portfolio

Featured News

Oxford Spinout Oxford Semantic Technologies acquired by Samsung Electronics
Oxford Spinout Oxford Semantic Technologies acquired by Samsung ElectronicsArticle links to www.oxionics.com
Oxford Ionics breaks global quantum performance records
Oxford Ionics breaks global quantum performance records
Times Commentary: Science innovation must be at the heart of government action
Times Commentary: Science innovation must be at the heart of government actionArticle links to www.beacontx.com
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene TherapiesArticle links to www.prnewswire.com
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptography
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptographyArticle links to www.globenewswire.com
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raises
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raisesArticle links to www.businesswire.com
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group

All News

Portfolio NewsTheolyticsTheolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UKPortfolio NewsTheolyticsTheolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investorPortfolio NewsTheolyticsMike Grey appointed Executive Chair of Theolytics’ Board of DirectorsPortfolio NewsTheolyticsTheolytics presents data at ESMO on its lead program being developed for Ovarian CancerPortfolio NewsTheolyticsTheolytics presents data on THEO-260 and THEO-310 at ASCO and EHAPortfolio NewsTheolyticsTheolytics presents CAF-targeting therapy for stromal rich tumours and strengthens leadership teamPortfolio NewsTheolyticsTheolytics' £1m project with Innovate UK to develop a novel therapy for multiple myeloma patientsPortfolio NewsTheolyticsTheolytics expands Series A financing and welcomes M Ventures as a new investorPortfolio NewsTheolyticsTheolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies